Protective Effects of Hydrogen-Rich Saline Against Lipopolysaccharide-Induced Alveolar Epithelial-to-Mesenchymal Transition and Pulmonary Fibrosis
Dong WW, Zhang YQ, Zhu XY, Mao YF, Sun XJ, Liu YJ, Jiang L. · Medical science monitor : international medical journal of experimental and clinical research. 2017;23:2357-2364.
What kind of evidence is this?
Preclinical
Controlled preclinical study
Respiratory health
Other forms
Not reported in this record.
Not reported in this record.
Methods at a glance
mice, tissues, tissue, cell used to study respiratory health.
Preclinical study; the full text reports 105 mice, with group/assay counts including n=21, n=84, n=7.
28 days
Full text reports H₂ dissolved in saline. Detected intervention quantities or schedules: 10 ml/kg, 28 days, 0.8 mmol/L.
H₂ dissolved in saline — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 10 ml/kg, 28 days, 0.8 mmol/L. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
oxidative-stress and antioxidant markers, apoptosis or cell injury, histology or tissue damage, neurological or behavioral measures, respiratory measures
Article-reported result excerpt (24 words maximum): “Based on these findings, the present study examined whether LPS-induced lung fibrosis was improved by hydrogen-rich saline treatment for 4 weeks.” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. The full article contains a conflict, commercial-support or supplied-product declaration; consult the source wording.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 28522797 · DOI: 10.12659/msm.900452
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10